Company Profile

Medeia is a powerful and cost effective engine for advancing biomedical inventions from idea to non-clinical proof-of-concept.  We have several programs in our R&D pipeline with the ultimate goal to develop novel treatments for devastating degenerative human diseases. The core therapeutic areas include diseases of the central nervous system (CNS) such as Alzheimer’s disease, Parkinson's disease and Amyotrophic lateral sclerosis and hormonal oncology.

Medeia's pipeline consists of non-clinical programs that stem from internal research and inventions. Medeia is committed to seeking partnerships with global pharmaceutical and biotech companies to advance our products further to clinical trials and eventually to the market. We also seek collaborators with cutting edge technologies or early stage programs in target validation or hit identification stages to complement our objectives.

Medeia’s track record in commercializing innovative therapeutic principles is convincing. We have entered into a research and option-based agreement with a leading pharmaceutical company to advance new chemical entities (NCEs) invented by Medeia  into clinical trials.